New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
11:08 EDTADSK, RDN, PLCE, BRLI, AVGOHigh option volume stocks: RDN AVGO PLCE ADSK BRLI
News For RDN;AVGO;PLCE;ADSK;BRLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 27, 2015
08:23 EDTAVGOAvago story remains compelling following results, says Brean Capital
Brean Capital said the Avago story remains compelling after the company reported a solid Q2 beat after competitors gave cautious commentary. Brean Capital reiterated its Buy rating on shares, citing valuation, expectations for better operating expenses, and a "world class" diversified semiconductor portfolio, but lowered its price target to $170 from $180 on Avago.
August 26, 2015
20:03 EDTAVGOOn The Fly: After Hours Movers
Subscribe for More Information
17:24 EDTAVGOAvago says FBAR capacity may remain pressured for 'extended' time period
Subscribe for More Information
16:07 EDTAVGOAvago sees Q4 GAAP revenue $1.84B plus or minus $25M, consensus $1.86B
Subscribe for More Information
16:06 EDTAVGOAvago reports Q3 EPS $2.24, consensus $2.14
Reports Q3 revenue $1.74B, consensus $1.74B.
15:00 EDTAVGONotable companies reporting after market close
Subscribe for More Information
10:00 EDTPLCEOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:15 EDTBRLIOPKO CEO Frost issues letter to shareholders on Bio-Reference deal
OPKO Health (OPK) chairman and CEO Phillip Frost released a letter to shareholders regarding the recently announced acquisition of Bio-Reference Laboratories (BRLI). "The strategy behind the recent Bio-Reference acquisition is twofold. First, it is a business whose revenues and profits have grown consistently since its launch by Dr. Marc Grodman in the 1980's, primarily through organic growth, to become the third largest full service reference laboratory in the United States," the letter reads. "It has built a reputation of innovation with recognized franchises in women's health, cancer and, more recently, genetics, helping physicians worldwide to diagnose rare genetic disorders and to identify special features of a patient's genetic material to select more effective chemotherapy. Second, it provides an infrastructure for marketing and sales that reaches approximately 10M patients a year." The letter adds that the 4Kscore test confirms elevated PSA tests have reduced costs by roughly $1B and, if the costs of downstream treatment interventions are also considered, there could be $2.5B additional annual savings to the U.S. health care system. "Among the many compelling reasons for the acquisition, we believe Bio-Reference will greatly accelerate the commercial success of the 4Kscore test," the letter continues. "Bio-Reference has the capacity to dramatically increase the number of 4Kscore tests done each day. They provide national marketing and distribution with a large client services group and a large dedicated sales force that already have strong relationships with primary care physicians. Bio-Reference has over 1,200 phlebotomists and 180 blood-draw centers around the country that can facilitate patient access. Finally, Bio-Reference has robust billing operations and a seasoned national reimbursement team that participates in almost every major commercial insurance plan. Bio-Reference has the expertise and extensive infrastructure to help make the 4Kscore test the new standard for identifying aggressive prostate cancer in men with a suspicious PSA." To close the letter, Frost wrote, "Given Bio-Reference's historical seasonal trends, we expect the second half of 2015 to show continuing growth in earnings and profits. We further expect that the contributions of Bio-Reference, FineTech and EirGen, will create positive EBITDA, or earnings before interest, income taxes, depreciation and amortization, for OPKO. Finally, we expect to continue to invest in research and development activities which, if successful, will result in ongoing improvement of our financial performance."
07:46 EDTPLCEChildren's Place upgraded to Positive at Susquehanna
As reported previously, Susquehanna upgraded Children's Place to Positive from Neutral. The firm cited its strong financial position, return of capital to shareholders via stock buybacks and dividends and its continued improvement in inventory utilization. Susquehanna raised its price target to $69 from $68 on Children's Place shares.
06:40 EDTPLCEChildren's Place upgraded to Positive from Neutral at Susquehanna
Subscribe for More Information
August 25, 2015
13:42 EDTADSKAutodesk volatility elevated into Q2 and outlook
Autodesk September call option implied volatility is at 46, October is at 40, January is at 35; compared to its 52-week range of 21 to 48, suggesting large near term price movement into the expected release of Q2 results on August 27.
09:59 EDTAVGOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:30 EDTAVGO, AVGOAvago upgraded to Buy from Outperform at CLSA
Subscribe for More Information
07:05 EDTPLCEChildren's Place narrows FY15 EPS view to $3.35-$3.45 from $3.30-$3.45
Subscribe for More Information
07:03 EDTPLCEChildren's Place sees Q3 EPS $1.90-$1.96, consensus $1.96
Sees Q3 SSS up 1%.
07:02 EDTPLCEChildren's Place reports Q2 adjusted EPS (33c), consensus (11c)
Subscribe for More Information
August 24, 2015
15:09 EDTPLCENotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Best Buy (BBY), consensus 34c... Toll Brothers (TOL), consensus 49c... Valspar (VAL), consensus $1.26... DSW (DSW), consensus 42c... Children's Place (PLCE), consensus (33c).
09:45 EDTAVGOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:27 EDTAVGOAvago downgraded to Sell from Hold at Drexel Hamilton
Drexel Hamilton downgraded Avago (AVGO) to Sell and reduced its price target to $95 from $125. The firm said Broadcom (BRCM) acquisition will require large amounts of debt and financing will be difficult given the situation in the capital markets.
06:22 EDTAVGOTSMC pursuing 16nm chip orders, DigiTimes reports
According to market sources, DigiTimes reports that TSMC (TSM) has been "actively" seeking 16nm FinFET chip orders. In addition to securing a portion of Apple's (AAPL) A9 chip orders, TSMC has also received orders from AMD (AMD), Broadcom (BRCM), LG, Nvidia (NVDA) and Avago (AVGO), the sources say, noting that TSMC failed to maintain orders for Qualcomm's (QCOM) flagship mobile chips, as it has placed orders for the Snapdragon 820 series with Samsung (SSNLF). Reference Link
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use